PAM
SPRO icon

Panagora Asset Management’s Spero Therapeutics SPRO Stock Holding History

Panagora Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,109
Closed -$31K – 2942
2021
Q1 		$31K Hold
2,109
– – ﹤0.01% 2256
2020
Q4 		$41K Sell
2,109
-8,224
-80% -$128K ﹤0.01% 2084
2020
Q3 		$115K Sell
10,333
-21,372
-67% -$253K ﹤0.01% 1750
2020
Q2 		$429K Buy
31,705
+17,256
+119% +$194K ﹤0.01% 1254
2020
Q1 		$115K Sell
14,449
-26,584
-65% -$234K ﹤0.01% 1651
2019
Q4 		$394K Sell
41,033
-9,713
-19% -$105K ﹤0.01% 1382
2019
Q3 		$538K Buy
50,746
+50,583
+31,033% +$533K ﹤0.01% 1260
2019
Q2 		$2K Buy
+163
New +$1.96K ﹤0.01% 2539

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Panagora Asset Management's SPRO Position: Q2 2021 in Review

Panagora Asset Management sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 2,109 shares — an estimated $31K sold.

Panagora Asset Management first reported a position in SPRO in Q2 2019 and held it in 8 quarters. The position peaked at $538K in Q3 2019. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

  • Panagora Asset Management reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Panagora Asset Management sold 2,109 Spero Therapeutics shares in Q2 2021, an estimated $31K.
  • Panagora Asset Management first reported a position in Spero Therapeutics in Q2 2019 and held it in 8 quarters.
  • Panagora Asset Management's Spero Therapeutics position peaked at $538K in Q3 2019.
  • 88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.